Teva Pharmaceuticals Axes Phase 2 Asthma Trial

Teva Pharmaceuticals has halted a phase 2 trial of TEV-48574, an investigational biologic drug for asthma patients, after interim results indicated that the treatment is unlikely to provide a significant benefit.

The study, which enrolled 65 asthma patients who were randomized to receive either TEV-48574 or placebo, failed to meet the benefit criteria based on several clinical measures, the company said.

Despite the halting of the asthma trial, TEV-48574 is in an ongoing phase 2 study for the treatment of inflammatory bowel disease.